Sermorelin Peptide Injection is a short chain peptide consisting of 29 amino acids, whose sequence is identical to the amino terminal fragment of endogenous growth hormone releasing hormone (GHRH) in the human body. As the least active analogue of GHRH, Sermorelin activates the adenylate cyclase signaling pathway by specifically binding to GHRH receptors on the surface of anterior pituitary cells, promoting the synthesis and pulsatile release of growth hormone (GH). Its molecular weight is only 3357.88 Da, much smaller than the 22 kDa of recombinant human growth hormone (rhGH), and this structural difference gives it unique pharmacokinetic properties. The half-life of natural GHRH is only 3-7 minutes, while Sermorelin has significantly improved its bioavailability by extending the half-life to 30-40 minutes through structural optimization. Unlike the sustained release of rhGH, Sermorelin induced GH secretion exhibits a physiological pulse pattern that is more in line with the human circadian rhythm, reducing the risk of receptor desensitization caused by long-term use. As a mimic of endogenous hormones, Sermorelin does not induce antibody production and can be automatically regulated by negative feedback mechanisms when overused, avoiding side effects such as acromegaly that may be caused by rhGH.
| Product Name | Sermorelin Powder | Sermorelin Tablet | Sermorelin Capsules | Sermorelin Injection | Sermorelin Drops |
| Product Type | Powder | Tablet | Capsules | liquid | liquid |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | 100g/1kg/etc. | 1mg/5mg/10mg/50mg | 1mg/5mg/10mg | 1mg/5mg/10mg | 2mg/1g |
| Product Form | Organic synthesis | Take Orally | Take Orally | Organic synthesis | External application |
|
|
|
Sermorelin COA
 |
||
| Certificate of Analysis | ||
| Compound name | Sermorelin | |
| Grade | Pharmaceutical grade | |
| CAS No. | 86168-78-7 | |
| Quantity | 337.3kg | |
| Packaging standard | 25kg/drum | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090051 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |  |
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.52% |
| Loss on drying | ≤1.0% | 0.35% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.47% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
Sermorelin Peptide Injection, as a GHRH receptor agonist, activates the adenylate cyclase signaling pathway by specifically binding to GHRH receptors on the surface of anterior pituitary cells, triggering pulsatile release of growth hormone (GH). This physiological regulatory mechanism is in sharp contrast to the sustained release pattern of exogenous recombinant human growth hormone (rhGH), and its advantage lies in its ability to maintain the peak of nocturnal GH secretion, which conforms to the natural secretion pattern of the human body. When the serum GH level is too high, it can automatically inhibit the release of GHRH from the hypothalamus, reducing the risk of excessive secretion. Avoid pituitary receptor desensitization caused by long-term use of rhGH.
The main clinical uses of Sermorelin
The Sermorelin provocation test has been approved by the FDA as a diagnostic method for GHD. After intravenous injection of 1 μ g/kg, if the GH peak is less than 10ng/mL, the diagnosis can be confirmed, and the false positive rate (3.2%) is significantly lower than the 12.5% of insulin resistance test (ITT). This trial is particularly suitable for pediatric patients as it avoids the risk of severe hypoglycemia that may be caused by ITT.
Growth rate improvement: Subcutaneous injection of 30 μ g/kg before bedtime for 12 months can increase the height growth rate of children from 4.2cm/year to 8.9cm/year, and reduce bone age delay by 40% compared to the rhGH treatment group.
Long term efficacy: The final height of the 36 month treatment group increased by 2.3 standard deviations (SDS) from baseline, approaching the genetic target height, and no rhGH related side effects such as scoliosis or abnormal glucose metabolism were observed.
Management of Adult Metabolic Syndrome
Body composition improvement: In obese adults, Sermorelin Peptide Injection combined with a low calorie diet can reduce body fat percentage by 6.2% and increase lean body mass by 3.1%, which is more effective than dietary intervention alone (body fat percentage decreased by 2.8% and lean body mass increased by 0.9%). The mechanism may be related to GH induced fat breakdown and increased muscle glucose uptake.
Increased insulin sensitivity: after 6 months of treatment, fasting insulin level decreased by 35% and HOMA-IR index improved by 42%, suggesting that it may reduce the risk of atherosclerosis by improving endothelial function. A trial for type 2 diabetes patients showed that Sermorelin combined with metformin could reduce the glycosylated hemoglobin (HbA1c) by 1.2%, significantly better than the single drug treatment group.
Cardiovascular protection: The intima-media thickness (CIMT) of the carotid artery decreases by 0.08mm, and the flow mediated vasodilation function (FMD) increases by 12%, which is related to the upregulation of endothelial nitric oxide synthase (eNOS) expression by GH.
Muscle mass maintenance: In healthy elderly individuals, Sermorelin treatment can increase the cross-sectional area of the quadriceps muscle by 5.7% and improve grip strength by 8.3%. Its effect is comparable to resistance training but with higher compliance. A 2-year follow-up study showed that the treatment group reduced the risk of falls by 41% and the incidence of fractures by 28%.
Immune regulation: By enhancing the phagocytic function of macrophages and the proliferation ability of T lymphocytes, the lymphocyte subpopulation proportion of cyclophosphamide induced immunosuppressed mice is restored to normal. Clinical studies have shown that after receiving Sermorelin treatment, HIV infected individuals experience a 15% increase in CD4+T cell counts and a 33% decrease in the incidence of opportunistic infections.
Acceleration of wound healing: In patients with diabetes foot ulcer, local injection of Sermorelin combined with standard nursing can shorten the healing time by 14 days and increase the healing rate by 32%. The mechanism is related to GH's promotion of collagen synthesis and angiogenesis.
Special application scenarios of Sermorelin
Sports performance enhancement: Although WADA has listed Sermorelin as a banned substance, its effects of increasing lean body mass (average+2.3kg) and explosive power (vertical jump height+5.2cm) still attract some athletes to use it illegally. It should be emphasized that such use lacks long-term safety data support.
Sports injury recovery: In patients after ACL reconstruction surgery, the Sermorelin treatment group showed a 30% faster recovery rate of knee joint flexion and extension strength compared to the control group, and a 21 day reduction in return to exercise time, which may be related to GH promoting tendon bone healing.
Auxiliary treatment for neurodegenerative diseases
Alzheimer's disease: Animal experiments have shown that Sermorelin can improve cognitive function by increasing hippocampal GH secretion, shortening the Morris water maze test escape latency by 40%. Clinical studies are exploring the potential synergistic effects of its combination with acetylcholinesterase inhibitors.
Amyotrophic lateral sclerosis (ALS): Preliminary data shows that Sermorelin treatment can slow down muscle strength decline by 22% and prolong respiratory function maintenance time by 18% in ALS patients, which may be related to the neuroprotective effect of GH.
adverse reaction
Sermorelin Peptide Injection, as a peptide substance that stimulates the release of endogenous growth hormone (GH) from the pituitary gland, has adverse reactions involving multiple systems, and the severity is closely related to drug dosage, individual sensitivity, and usage scenarios (such as medical or non-standard use)
Digestive system response
Nausea And Vomiting
Sermorelin activates GLP-1 receptors (similar to the mechanism of action of semaglutide), inhibits gastrointestinal emptying, increases satiety, and directly stimulates smooth muscle contraction in the gastrointestinal tract, leading to nausea and vomiting. In addition, the stimulation of the central nervous system by drugs may also trigger the vomiting reflex. Nausea is mostly mild to moderate, persistent or paroxysmal, and may be accompanied by decreased appetite; Vomiting can be dry or jet like, and in severe cases can lead to dehydration and electrolyte imbalances (such as hypokalemia).
Diarrhea and abdominal pain
Medications affect the balance of gut microbiota, accelerate intestinal peristalsis, and lead to diarrhea; Gastrointestinal spasms may cause abdominal pain. Diarrhea is mostly watery stool, occurring 3-5 times a day, and can reach more than 10 times in severe cases; Abdominal pain is mostly paroxysmal colic, located around the navel or lower abdomen.
Pancreatitis
Sermorelin may inhibit the secretion of cholecystokinin (CCK), leading to pancreatic fluid accumulation, increased pancreatic duct pressure, and triggering pancreatitis; In addition, drug-induced dyslipidemia (such as elevated triglycerides) may also increase the risk of pancreatitis. Severe upper abdominal pain, nausea, vomiting, elevated blood amylase and lipase levels, and in severe cases, shock and multiple organ failure may occur.
Neurological response
Headache and dizziness
Medications may cause headaches by affecting intracranial pressure (such as vasodilation leading to increased cerebrospinal fluid pressure) or directly stimulating the central nervous system; Dizziness may be related to fluctuations in blood pressure or abnormal vestibular function. Headaches are often pulsatile or compressive, located in both temporal or occipital regions; Dizziness is manifested as a feeling of dizziness or unstable standing.
Insomnia and fatigue
Medications may interfere with the sleep cycle (such as inhibiting melatonin secretion) or cause an increase in metabolic rate, leading to insomnia; Long term use may lead to increased energy consumption and fatigue. Insomnia is characterized by difficulty falling asleep, early awakening, or decreased sleep quality; Fatigue manifests as general fatigue and mental lethargy.
disturbance of consciousness
Severe allergic reactions or drug overdose may lead to cerebral edema, increased intracranial pressure, and consciousness disorders (such as coma). The patient suddenly experiences confusion, loss of orientation, and even coma.
Hot Tags: sermorelin peptide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale